Is there any relationship between imatinib mesylate medication and hypothalamic-pituitary-adrenal axis dysfunction?

• Published in: International journal of clinical practice (Esher) Vol. 64; no. 1; pp. 45 - 50
• Main Authors: Bilgir, O., Kebapcilar, L., Bilgir, F., Sarì, I., Oner, P., Karaca, B., Alacacioglu, I.
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 01.01.2010; John Wiley & Sons, Inc
• Subjects: Adrenocorticotropic Hormone; Adult; Aged; Antineoplastic Agents - adverse effects; Benzamides; Cosyntropin; Endocrine System Diseases - chemically induced; Endocrine System Diseases - metabolism; Endocrinology; Female; Glucagon; Glucocorticoids - deficiency; Hormones; Humans; Hydrocortisone - metabolism; Hypothalamo-Hypophyseal System - drug effects; Imatinib Mesylate; Inhibitor drugs; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism; Male; Middle Aged; Pharmacology; Piperazines - adverse effects; Pituitary-Adrenal System - drug effects; Protein Kinase Inhibitors - adverse effects; Pyrimidines - adverse effects

Summary Background:  Imatinib mesylate [tyrosine kinase (TK) inhibitor] is a novel medication in the treatment of chronic myelogenous leukaemia (CML). TK is also essential in hypothalamo‐pituitary‐adrenal (HPA) axis. Purpose:  The aim of this study was to evaluate HPA axis in patients treated with i...